Drug Profile
Pexidartinib - Daiichi Sankyo
Alternative Names: Pexidartinib hydrochloride; Plexxikon 3397; PLX-3397; TURALIOLatest Information Update: 13 Nov 2023
Price :
$50
*
At a glance
- Originator Plexxikon
- Developer Array BioPharma; AstraZeneca; Barbara Ann Karmanos Cancer Institute; Columbia University; Daiichi Sankyo Company; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Cancer Institute (USA); Plexxikon; The Christie NHS Foundation Trust; University of California at San Francisco
- Class 2 ring heterocyclic compounds; Antidementias; Antineoplastics; Fluorine compounds; Pyridines; Pyrroles; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Macrophage colony stimulating factor receptor antagonists; Proto oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Giant cell tumour of tendon sheath
- Phase II Acral lentiginous melanoma; Glioblastoma; Malignant melanoma; Prostate cancer
- Phase I/II Acute myeloid leukaemia; Breast cancer; Gastrointestinal stromal tumours; Leukaemia; Sarcoma; Solid tumours
- No development reported Colorectal cancer; Pancreatic cancer
- Discontinued Alzheimer's disease; Hodgkin's disease; Neurological disorders; Rheumatoid arthritis
Most Recent Events
- 13 Nov 2023 Daiichi Sankyo Company announces intention to submit regulatory applications for approval for Giant cell tumour of tendon sheath in some undisclosed countries/regions (Daiichi Sankyo Company pipeline, November 2023)
- 22 Feb 2023 Pexidartinib is still in phase III trial for Giant cell tumour of tendon sheath in Japan (PO) (Daiichi Sankyo pipeline, February 2023)
- 22 Feb 2023 Pexidartinib is still in phase III trial for Giant cell tumour of tendon sheath in Taiwan, China (PO) (NCT04488822)